top of page

Stem Cell–Derived Islet Therapy Showing Insulin Production in Human Trials for Type 1 Diabetes

Writer: Zarina Ali
Zarina Ali
Jun 27
3 min read

How Vertex Is Advancing Cell Replacement Treatment


For many people with Type 1 Diabetes, treatment means lifelong insulin therapy. While insulin delivery technology has improved significantly, it does not replace the insulin-producing cells destroyed by the immune system.


Vertex Pharmaceuticals is developing a stem cell–derived islet cell therapy designed to restore the body’s ability to produce insulin naturally.



Step 1: The Problem Type 1 Diabetes Creates


Type 1 Diabetes is an autoimmune disease in which the immune system destroys pancreatic beta cells, which produce insulin.


Without these cells, the body loses its ability to regulate blood sugar.


Current treatment includes:

  • Insulin injections or pumps

  • Continuous glucose monitoring

  • Constant dose adjustments


While effective, this approach manages the disease rather than replacing the missing biological function.


Step 2: The Idea Behind Cell Replacement Therapy


Researchers have long explored the idea that Type 1 Diabetes could be treated by replacing the destroyed beta cells.


Vertex’s approach uses:

  • Stem cell–derived islet cells created in a laboratory

  • Cells that behave like natural pancreatic beta cells

  • Transplantation into the body


Once transplanted, these cells can:

  • Detect blood glucose levels

  • Produce insulin automatically

  • Help restore natural glucose regulation


This approach is known as cell replacement therapy.


Step 3: VX-880 (Zimislecel) Development


Vertex’s therapy, originally known as VX-880 and now called zimislecel, uses lab-grown islet cells derived from stem cells.


These cells are infused into the body through a procedure similar to traditional islet transplantation, where they travel to the liver and begin functioning as insulin-producing cells.


The goal is straightforward:

Restore natural insulin production in people with Type 1 Diabetes.


Step 4: Early Human Clinical Results


In early clinical trials, Vertex’s therapy has shown promising results in humans.


Reported outcomes include:

  • Significant reductions in daily insulin requirements

  • Improved blood glucose control

  • Some participants becoming insulin-independent for periods of time


These results represent some of the strongest early evidence that stem cell–derived islet cells can function inside the human body.


However, these studies are still ongoing, and outcomes may vary between participants.


Step 5: The Main Limitation — Immune Rejection


Despite its promise, Vertex’s therapy still faces a major challenge: the immune system.


Because the transplanted islet cells are recognized as foreign, the body may attack them.


To prevent rejection, participants must take immunosuppressive medications, which:

  • Increase infection risk

  • Require long-term medical monitoring

  • Carry potential side effects over time


This means the therapy is not yet a cure, even though it can restore insulin production in some patients.


Step 6: Why This Research Matters


Vertex’s work represents one of the most advanced examples of stem cell–based treatment for Type 1 Diabetes currently in human trials.


Unlike insulin therapy, which manages symptoms, this approach aims to:

  • Replace lost biological function

  • Restore insulin production

  • Reduce or eliminate insulin dependence in some cases


It is one of the clearest demonstrations so far that cell replacement therapy can work in humans.


Step 7: Where the Research Is Going Next


Vertex continues to study zimislecel in clinical trials to better understand:

  • Long-term survival of transplanted cells

  • Consistency of insulin production

  • Safety of immunosuppressive therapy

  • Reproducibility of results across more patients


Future research may also explore ways to reduce or eliminate the need for immunosuppression, which remains one of the biggest barriers to widespread use.


Final Takeaway


Vertex’s stem cell–derived islet therapy is one of the most promising advances in Type 1 Diabetes research today.


While still experimental, early human trials show that restoring insulin production through cell replacement is possible.


If future studies continue to show success, therapies like zimislecel could shift Type 1 Diabetes treatment from lifelong management toward partial biological restoration.


Research in 60 Seconds


Breakthrough: Stem cell–derived islet cells that produce insulin in the human body


Company: Vertex Pharmaceuticals


Goal: Replace destroyed beta cells and restore natural insulin production


Human Results: Some participants have significantly reduced or stopped insulin use in early trials


Limitation: Requires immunosuppressive medication to prevent rejection


Stage: Early clinical trials (zimislecel / VX-880)


Why It Matters: This is one of the most advanced stem cell therapies in humans so far, showing that restoring insulin production in Type 1 Diabetes may be possible through cell replacement

 
 
 

Comments


bottom of page